Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: A study of timing and the impact of malignant dedifferentiation

Journal of the American College of Surgeons

Volumn 211, Issue 4, 2010, Pages 526-535

  Chua, Terence C ^a   Al Zahrani, Abdulaziz ^a   Saxena, Akshat ^a   Liauw, Winston ^b   Zhao, Jing ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

CC; Completeness of cytoreduction; Early postoperative intraperitoneal chemotherapy; EPIC; HIPEC; Hyperthermic intraperitoneal chemotherapy; Perioperative intraperitoneal chemotherapy; PIC; PMP; Pseudomyxoma peritonei

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; MITOMYCIN C; MITOMYCIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CELL DEDIFFERENTIATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DATA BASE; DISEASE COURSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; CELL DIFFERENTIATION; CELL TRANSFORMATION; INFUSION; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; PSEUDOMYXOMA PERITONEI; SURVIVAL; TIME;

ADULT; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; MITOMYCIN; PERITONEAL NEOPLASMS; PROGNOSIS; PSEUDOMYXOMA PERITONEI; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957224541     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2010.06.011     Document Type: Article

References (20)

1. B.J. Moran, and T.D. Cecil The etiology, clinical presentation, and management of pseudomyxoma peritonei Surg Oncol Clin North Am 12 2003 585 603 (Pubitemid 36920087)
2. B.M. Ronnett, C.M. Zahn, and R.J. Kurman Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei" Am J Surg Pathol 19 1995 1390 1408
3. T.D. Yan, M. Links, and Z.Y. Xu Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms Br J Surg 93 2006 1270 1276 (Pubitemid 44547028)
4. D. Baratti, S. Kusamura, and D. Nonaka Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) Ann Surg Oncol 15 2008 526 534
5. B.M. Ronnett, H. Yan, and R.J. Kurman Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis Cancer 92 2001 85 91 (Pubitemid 32623044)
6. R.F. Bradley, J.H.T. Stewart, and G.B. Russell Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review Am J Surg Pathol 30 2006 551 559
7. P.H. Sugarbaker New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7 2006 69 76
8. J.W. Smith, N. Kemeny, and C. Caldwell Pseudomyxoma peritonei of appendiceal origin The Memorial Sloan-Kettering Cancer Center experience Cancer 70 1992 396 401
9. S.S. Nitecki, B.G. Wolff, R. Schlinkert, and M.G. Sarr The natural history of surgically treated primary adenocarcinoma of the appendix Ann Surg 219 1994 51 57 (Pubitemid 24032237)
10. D.B. Gough, J.H. Donohue, and A.J. Schutt Pseudomyxoma peritonei Long-term patient survival with an aggressive regional approach Ann Surg 219 1994 112 119
11. T.J. Miner, J. Shia, and D.P. Jaques Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy Ann Surg 241 2005 300 308
12. E.M. Murphy, S.M. Farquharson, and B.J. Moran Management of an unexpected appendiceal neoplasm Br J Surg 93 2006 783 792
13. T.C. Chua, T.D. Yan, and M.E. Smigielski Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution Ann Surg Oncol 16 2009 1903 1911
14. P. Jacquet, and P.H. Sugarbaker Current methodologies for clinical assessment of patients with peritoneal carcinomatosis J Exp Clin Cancer Res 15 1996 49 58 (Pubitemid 26130826)
15. P.H. Sugarbaker Peritonectomy procedures Ann Surg 221 1995 29 42
16. P. Jrvinen, H.J. Jrvinen, and A. Lepist Survival of patients with pseudomyxoma peritonei treated by serial debulking Colorectal Dis 2009 [Epub ahead of print]
17. A.L. Farquharson, N. Pranesh, and G. Witham A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei Br J Cancer 99 2008 591 596
18. J.F. Shapiro, J.L. Chase, and R.A. Wolff Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience Cancer 116 2010 316 322
19. D. Mller Appendiceal neoplasm resulting from a malignant transformation of a villous adenoma Chirurg 51 1980 609 610 (Pubitemid 10026285)
20. J.T. O'Connell, J.S. Tomlinson, and A.A. Roberts Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells Am J Pathol 161 2002 551 564